0000000000552660
AUTHOR
Manish Parikh
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…
TCT-16 Patient and Procedural Characteristics and In-Hospital Outcomes Associated With the Use of Retrograde Recanalization Techniques for Chronic Total Occlusion PCI: A Report from the Open CTO Registry
Since the introduction of the Hybrid Algorithm for Chronic Total Occlusion (CTO) PCI, the use of retrograde recanalization techniques has become more common. We sought to identify patient and procedural characteristics necessitating use of retrograde CTO techniques using a multicenter, adjudicated,